Neuropace FDA announcement
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Greetings. Welcome to the NeuroPace IGE PMA Supplement Update Call. At this time, all participants are in a listen-only mode. A question and answer session will follow prepared remarks. Please note this conference is being recorded. I will now turn the call over to Scott Schaper, Head of Investor Relations. Please go ahead. Good afternoon.
Thank you for joining today's conference call. On the call, we will hear from Joel Becker, NeuroPace's President and Chief Executive Officer, and Dr. Martha Morrell, NeuroPace's Chief Medical Officer. Patrick Williams, NeuroPace's Chief Financial Officer, is also on the line. Earlier today, NeuroPace issued a press release providing an update on the status of the company's PMA supplement, seeking to expand the indication for the RNS System to include patients with anti-seizure medication-resistant idiopathic generalized epilepsy, or IGE. A copy of the press release is available on the investor relations section of our website. Before we begin, I would like to remind you that certain statements made on today's call may constitute forward-looking statements within the meaning of Federal Securities laws.
These statements include, among others, comments regarding our expectations and beliefs with respect to regulatory matters, including FDA review of our PMA supplement through IGE, our Submission Issue Request process, our intent to amend the submission with supplemental information, our ability to place the PMA supplement in approvable form, potential labeling and post-approval study approaches, timing of future interactions with FDA, timelines for FDA review of PMA supplement amendments, the potential approval of an expanded indication, the potential clinical and commercial opportunity in IGE, and our expectations regarding operating performance and growth. Forward-looking statements are based on management's current expectations and assumptions informed by the information that is known at the time the statements are made. They are subject to risks and uncertainties that could cause actual results to differ materially.
A discussion of these risks and uncertainties can be found in today's press release and in our filings with the Securities and Exchange Commission, including our most recent Form 10-K and Form 10-Q. We undertake no obligation to update or revise any forward-looking statements except as required by law. With that, I'll now turn the call over to Joel Becker.
Joel? Thank you, Scott, and good afternoon, everyone.
As Scott mentioned, this afternoon we issued a press release providing an update on the FDA review of our PMA supplement seeking indication expansion for the RNS System into drug-resistant idiopathic generalized epilepsy, or IGE. Let me begin with the headline. We received communication from FDA on the status of our PMA supplement, indicating that our submission was not approvable in its current form due to additional information requested regarding the clinical evidence supporting the submission. Having reviewed FDA's written communications and had subsequent discussions with the agency, we believe there is a path for approval of the submission. Our interactions are now focused on providing the information needed to answer FDA's remaining questions.
While we are disappointed with not receiving an initial approval, we were encouraged by our subsequent discussion with the agency, and importantly, their interest in engaging interactively, their request for additional information to address certain questions, and their willingness to work collaboratively to bring the RNS indication expansion for drug-resistant IGE patients to market. We view our subsequent interactions with FDA as a constructive step in clarifying the path forward in the regulatory process. As I mentioned, following receipt of the communication and at the agency's invitation, we met with FDA to discuss their feedback. The review team and Office of Health Technology, consistent with the letter, indicated that providing additional data from the NAUTILUS trial and additional clinical context could help address the agency's remaining questions. Importantly, the submission not being approvable in its current form was not based on any new safety concern.
The primary safety endpoint in NAUTILUS was met, and the FDA communication did not identify any new safety signals with the RNS System. From a forward process standpoint, based on the strong recommendation from the agency, we are in the process of submitting a Submission Issue Request, or SIR, to further discuss our planned approach. A Submission Issue Request is a process that allows a sponsor to engage with FDA on specific issues in an active application. We expect to meet with the agency over the next few weeks, and this meeting gives us an opportunity to discuss our planned approach with FDA before submitting an amendment. We believe that is the right next step because it can help us align with FDA on the content and structure.
Following alignment with the agency as part of these interactions, we intend to amend the submission with supplemental information, including additional data and analysis regarding the patient populations evaluated in NAUTILUS, real-world evidence, and context with regard to the clinical meaningfulness of seizure reduction. I want to emphasize that we continue to believe in the strength of the NAUTILUS dataset and in the potential of the RNS System to address a significant unmet need for patients with drug-resistant IGE. These patients have no approved neuromodulation or surgical treatment options.
For patients who continue to experience uncontrolled generalized tonic-clonic seizures, the status quo is not without significant clinical risk. Dr. Morrell will walk through the clinical data in more detail. To close, we are working with urgency and discipline to develop the supplemental package aligned with FDA on appropriate data requests through the Submission Issue Request process and move the application forward to approval. I will now turn the call over to Dr. Morrell to discuss the clinical context and data.
Marty? Thank you, Joel, and thank you to everyone joining this afternoon.
Let's begin with the patient population. That is central to our conviction in this indication and our commitment to advancing a therapy for these patients who have a meaningful unmet clinical need. Patients with drug resistant idiopathic generalized epilepsy who continue to experience generalized tonic-clonic or GTC seizures face a substantial life burden and risk to safety. GTC seizures are among the most severe and dangerous seizure types. Each GTC seizure is a serious medical event that can involve sudden loss of consciousness, a fall, and convulsive movements of arms and legs, often leading to injury. Recovery may be prolonged and rescue medication is often required. Additionally, patients with uncontrolled GTCs have the highest risk of sudden unexpected death in epilepsy or SUDEP. Reducing GTC seizures can meaningfully improve patient safety, independence, and quality of life.
For these patients, as Joel said, there are no approved neuromodulation or surgical treatment options available today. That is the unmet need that the NAUTILUS study was designed to address. I will not review the study design in detail, but I want to remind you of a few points. NAUTILUS is the first prospective, multi-center, randomized, single blind, sham stimulation controlled study evaluating responsive thalamic stimulation using the RNS System in patients with drug resistant IGE. Importantly, the study met its primary safety endpoint. While the primary effectiveness endpoint did not achieve statistical significance, the pre-specified additional analyses comparing seizure frequency during treatment with baseline seizure frequency demonstrated statistically significant improvements. FDA has requested information to help them understand whether these improvements are clinically meaningful with a focus on certain patient subgroups. FDA wishes to consider this using the totality of evidence.
This includes the entirety of the data from the NAUTILUS trial, including additional effectiveness data at 24 months, analyses of response according to patient baseline seizure frequency, and detailed information on patient reported outcomes. Additionally, published literature will be provided that supports the clinical meaningfulness of the response to RNS System treatment. The clinical data generated in the NAUTILUS trial that was provided in the initial submission and what will be provided in the amendment consistently shows what we believe are meaningful and lasting improvements in outcomes that matter to patients and their physicians. The initial submission provided data to 18 months. At 18 months, patients treated with RNS System experienced a 77% median reduction in generalized tonic-clonic seizures compared with baseline. 40% of patients experienced GTC seizure freedom at that time point. We also saw rapid and sustained reductions in other generalized seizure types, including absence and myoclonic seizures.
The 18-month data also showed benefits beyond seizure counts. More than 90% of patients reported improvement on the Patient Global Impression of Change, and 80% of their physicians reported improvement on the Clinical Global Impression of Improvement. Responsive stimulation treatment was also associated with an approximate 30% reduction in seizure-related injury events and 44% lower odds of use of a benzodiazepine as a rescue medication for a generalized tonic-clonic seizure. Those data are now peer reviewed and recently published in "Epilepsia," which is important both scientifically and clinically. The publication provides level 1 evidence supporting responsive thalamic stimulation as a potential treatment approach for patients with drug resistant IGE. Since that 18-month analysis, the data set has continued to strengthen. At the request of the FDA during the review process, the company provided 24-month data, which showed patients continued to improve with stimulation.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
